This guest blog post is written by Poncho Meisenheimer, Vice President of Research and Development.

I got into an argument with ChatGPT this morning.

That’s not unusual. I argue with ChatGPT a lot. In fact, that’s usually my goal.

As a scientist and a leader, it’s important to pressure-test my ideas. I need to account for biases, identify limitations, and strengthen weak points. Large language models like ChatGPT have given me a powerful tool in my pocket to become a better version of myself.

The advent of generative artificial intelligence has changed our world. We can’t keep doing things the way we did even only a year ago.

Promega is embracing AI. Every department is finding groundbreaking and responsible ways to deepen their impact using our ChatGPT enterprise license. As the Vice President of Research and Development, I have been working with our scientists to think beyond simple queries and imagine new horizons we can explore with these tools. 

Make no mistake: I don’t think that ChatGPT and other AI tools can, will or should replace human scientists. Instead, they will empower all scientists to ask more ambitious questions and uncover new answers. They will upend our current paradigm about what science is and how it operates, and will help us build an even deeper understanding of the world around us.

Continue reading “AI in the Research Lab: Where We Are, and Where We’re Going”

On October 26, hundreds of young scientists made their way through Paris to convene at the Paris Expo Porte de Versailles for the world’s largest synthetic biology competition. The iGEM Grand Jamboree showcases student projects from around the world that tackle real-world challenges such as nutrition, diagnostics and climate change.

Each year, ten Promega iGEM Grant winners receive $2,500 in free Promega products to support their research. Many Promega branch offices also provide support to teams within their region. In total, 36 iGEM teams were supported by Promega during the 2022 competition.

Six representatives from Promega Madison, France and Germany attended the Jamboree. We met so many incredible scientists and had countless conversations about the exciting future of synthetic biology. At the Closing Ceremonies, we were thrilled to see many of our sponsored teams take home gold medals, trophies, and even the coveted BioBrick Trophy.

Continue reading “Recapping the 2022 iGEM Grand Jamboree”

Today’s blog is written by KCL iGEM Team Leaders Alya Masoud Abdelhafid and Luke Bateman. Both in their third and final year at King’s College London, Alya is completing a BSc in Nutrition and Luke a BSc in Biochemistry.  

Every year, the International Genetically Engineered Machine competition (iGEM) offers high-school, undergraduate and post-graduate students the opportunity to conduct independent research using synthetic biology and genetic engineering to develop solutions to local and global problems.

More than 350 teams from around the world participate in iGEM, which culminates in a presentation at the global iGEM Giant Jamboree, attended by more than 6000 people every year. Here, novel research is presented amongst pioneers in synthetic biology, and outstanding projects are awarded prizes for their contribution to the greater scientific community. iGEM teams consistently produce ground-breaking solutions to modern challenges, many of which facilitate the development of multimillion-dollar companies and start-ups.

We are the King’s College London (KCL) iGEM team and are honored to be involved in the innovative and prestigious iGEM community.

Continue reading “iGEM Team Explores Regenerative Spinal Cord Treatment with Promega Support”

In this blog, Dr. Jolanta Vidugiriene, Senior Research Scientist at Promega Corporation, discusses tools for studying metabolism in NAFLD/NASH research.

What is nonalcoholic fatty liver disease (NAFLD)?

NAFLD is not a simple disease, it is an umbrella term for a range of liver conditions. The main defining characteristic of NAFLD is fat accumulation in the liver, called steatosis. In about 20% of people, steatosis is accompanied by inflammation, which is a more severe form of NAFLD called NASH (nonalcoholic steatohepatitis). NASH can progress to more advanced conditions like liver cirrhosis and liver failure. Most of the time, NAFLD is associated with underlying conditions—it is closely related to metabolic dysfunction, obesity, and type 2 diabetes. To better reflect the disease pathology, there has been a lot of discussion in the field recently to rename NAFLD to MAFLD, for metabolic associated fatty liver disease. Even though NAFLD has been studied for many years, the causes and progression of the disease are still not well understood. There are no FDA-approved diagnostic tools or treatments for it yet.

Continue reading “Monitoring Cellular Metabolism for NAFLD/NASH Liver Disease Research”